Container Performance Testing - New Proposal for USP General Chapter <671>

Recommendation
7/8 October 2025
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
In Pharmacopoeial Forum 39 (2) a proposal for the revision of USP General Chapter <671> was published. According to the summary of this change package integrity is necessary to maintain the drug product's quality throughout its shelf life. Packaging systems have to demonstrate satisfactory container-closure integrity. It is proposed that this chapter will be revised to include a new permeation method for determining barrier protection for packaging systems.
The purpose of this chapter is to provide standards for the functional properties of packaging systems used for solid oral dosage forms and liquid dosage forms for pharmaceuticals. Test methods are provided to measure moisture vapour transmission rates that are useful for pharmaceutical manufacturers to determine the level of barrier protection provided by packaging systems. Additional methods are provided to determine classification of packaging systems.
Definitions and moisture vapour transmission rates at 40°/75% relative humidity (RH)are given for the following blisters:
- Low-barrier blister - greater than 1.0 mg/cavity-day
- High-barrier blister - less than 1.0 mg/cavity-day
- Ultra-high barrier blister - less than 0.01 mg/cavity-day
Other methods may be used, if these alternative methods are described in sufficient detail to
justify their use.
More information can be found in the USP's Pharmacopeial Forum (PF).
Source: USP
Related GMP News
18.09.2025USP-NF Stimuli Article on Apex Vessels used in Dissolution Testing: Corrected Version Published
18.09.2025Who is allowed to perform Sampling?
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations